Your browser doesn't support javascript.
loading
Reported antibiotic use among patients in the multicenter ANDEMIA infectious diseases surveillance study in sub-saharan Africa.
Wieters, Imke; Johnstone, Siobhan; Makiala-Mandanda, Sheila; Poda, Armel; Akoua-Koffi, Chantal; Abu Sin, Muna; Eckmanns, Tim; Galeone, Valentina; Kaboré, Firmin Nongodo; Kahwata, François; Leendertz, Fabian H; Mputu, Benoit; Ouedraogo, Abdoul-Salam; Page, Nicola; Schink, Susanne B; Touré, Fidèle Sounan; Traoré, Adjaratou; Venter, Marietjie; Vietor, Ann Christin; Schubert, Grit; Tomczyk, Sara.
Affiliation
  • Wieters I; Institute of Tropical Medicine and International Health, Charité- Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany. wietersi@rki.de.
  • Johnstone S; Robert Koch-Institute, Nordufer 20, 13353, Berlin, Germany. wietersi@rki.de.
  • Makiala-Mandanda S; Center for Enteric Diseases, National Health Laboratory Service, National Institute for Communicable Diseases, 1 Modderfontein Road, Sandringham, Johannesburg, 2131, South Africa.
  • Poda A; Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Akoua-Koffi C; Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
  • Abu Sin M; Centre Hospitalier Universitaire Sourô Sanou de Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso.
  • Eckmanns T; Centre Hospitalier Universitaire Bouaké, Bouaké, Ivory Coast.
  • Galeone V; Université Alassane Ouattara de Bouaké, Bouaké, Ivory Coast.
  • Kaboré FN; Robert Koch-Institute, Nordufer 20, 13353, Berlin, Germany.
  • Kahwata F; Robert Koch-Institute, Nordufer 20, 13353, Berlin, Germany.
  • Leendertz FH; Robert Koch-Institute, Nordufer 20, 13353, Berlin, Germany.
  • Mputu B; Centre Muraz, Bobo-Dioulasso, Burkina Faso.
  • Ouedraogo AS; Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
  • Page N; Helmholtz Institute for One Health, Fleischmannstraße 42, 17489, Greifswald, Germany.
  • Schink SB; Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
  • Touré FS; Centre Hospitalier Universitaire Sourô Sanou de Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso.
  • Traoré A; Centre Muraz, Bobo-Dioulasso, Burkina Faso.
  • Venter M; School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, 31 Bophelo Rd, Prinshof 349-Jr, Pretoria, 0084, South Africa.
  • Vietor AC; Department of Medical Virology, University of Pretoria, Pretoria, South Africa.
  • Schubert G; Robert Koch-Institute, Nordufer 20, 13353, Berlin, Germany.
  • Tomczyk S; Centre Hospitalier Universitaire Bouaké, Bouaké, Ivory Coast.
Antimicrob Resist Infect Control ; 13(1): 9, 2024 01 25.
Article in En | MEDLINE | ID: mdl-38273333
ABSTRACT

BACKGROUND:

Exposure to antibiotics has been shown to be one of the drivers of antimicrobial resistance (AMR) and is critical to address when planning and implementing strategies for combatting AMR. However, data on antibiotic use in sub-Saharan Africa are still limited. Using hospital-based surveillance data from the African Network for Improved Diagnostics, Epidemiology and Management of Common Infectious Agents (ANDEMIA), we assessed self-reported antibiotic use in multiple sub-Saharan African countries.

METHODS:

ANDEMIA included 12 urban and rural health facilities in Côte d'Ivoire, Burkina Faso, Democratic Republic of the Congo, and Republic of South Africa. Patients with acute respiratory infection (RTI), acute gastrointestinal infection (GI) and acute febrile disease of unknown cause (AFDUC) were routinely enrolled, and clinical, demographic, socio-economic and behavioral data were collected using standardized questionnaires. An analysis of ANDEMIA data from February 2018 to May 2022 was conducted. Reported antibiotic use in the ten days prior to study enrolment were described by substance and by the WHO AWaRe classification ("Access", "Watch", "Reserve", and "Not recommended" antibiotics). Frequency of antibiotic use was stratified by location, disease syndrome and individual patient factors.

RESULTS:

Among 19,700 ANDEMIA patients, 7,258 (36.8%) reported antibiotic use. A total of 9,695 antibiotics were reported, including 54.7% (n = 5,299) from the WHO Access antibiotic group and 44.7% (n = 4,330) from the WHO Watch antibiotic group. The Watch antibiotic ceftriaxone was the most commonly reported antibiotic (n = 3,071, 31.7%). Watch antibiotic use ranged from 17.4% (56/322) among RTI patients in Côte d'Ivoire urban facilities to 73.7% (630/855) among AFDUC patients in Burkina Faso urban facilities. Reported antibiotic use included WHO Not recommended antibiotics but no Reserve antibiotics.

CONCLUSIONS:

Reported antibiotic use data from this multicenter study in sub-Saharan Africa revealed a high proportion of WHO Watch antibiotics. Differences in Watch antibiotic use were found by disease syndrome, country and health facility location, which calls for a more differentiated approach to antibiotic use interventions including further evaluation of accessibility and affordability of patient treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Communicable Diseases / Anti-Bacterial Agents Type of study: Clinical_trials / Screening_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: Antimicrob Resist Infect Control Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Communicable Diseases / Anti-Bacterial Agents Type of study: Clinical_trials / Screening_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: Antimicrob Resist Infect Control Year: 2024 Document type: Article Affiliation country:
...